Relationship between expression of PD-1 and CD39 and clinicopathological features and prognosis of gastric cancer
Objective To analyze the expression of PD-1 and CD39 in CD8+T cells in cancer tissues,para-cancer tissues and peripheral blood of the patients with gastric cancer,and the relationship between clinical features and prognosis.Methods The expression levels of PD-1 and CD39 in cancer tissues,paracancer and 14 peripheral blood CD8+T cells of 38 gastric cancer patients who were initially treated in the hospital from January 1,2022 to December 1,2023 were detected by flow cytometry.The correlation between the expression levels of PD-1 and CD39 in CD8+T cells and the pathological characteristics of gastric cancer pa-tients was further analyzed,and the prognostic analysis was performed using KM-plotter database.Results The expression levels of PD-1 and CD39 on CD8+T cells in gastric cancer tissues were higher than those in pa-racancer tissues[36.6％(27.9％,52.8％)vs 14.1％(8.1％,23.2％),2.9％(1.1％,6.6％)vs 1.4％(0.5％,3.5％)],there was statistical significance(P＜0.05).The expression levels of PD-1 and CD39 on CD8+T cells in cancer tissues were higher than those in peripheral blood(P＜0.05).The expression level of PD-1 was related to pathological type,differentiation degree,nerve invasion and pre-treatment neutrophil-to-lymphocyte ratio(NLR),and the differences were statistically significant(P＜0.05).The expression level of CD39 on CD8+T cells in cancer tissues was correlated with smoking history(P＜0.05).According to KM-plotter database analysis,the patients with low expression of PD-1 had a longer survival time than those with high expression of PD-1,the difference was statistically significant(P＜0.05);the patients with low expression of CD39 had a longer survival period than those with high expres-sion of CD39,the difference was statistically significant(P＜0.05).Conclusion The expression levels of PD-1 and CD39 on CD8+T cells in gastric cancer patients are related to prognosis and may provide the ref-erence for selecting dual targets for immunotherapy in gastric cancer.
万方数据
维普
